<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611816</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0538</org_study_id>
    <secondary_id>2017-A03327-46</secondary_id>
    <nct_id>NCT03611816</nct_id>
  </id_info>
  <brief_title>Biological Bank for Atrial Fibrillation and Stroke</brief_title>
  <acronym>BAFA</acronym>
  <official_title>Biological Bank for Studies Related to Atrial Fibrillation and Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical
      practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on
      people over 65 years.

      According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial
      fibrillation has significant genetic heterogeneity. About 40 genes have been identified as
      potentially involved. Studies have identified genes common to the risk of atrial fibrillation
      and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and
      extensively studied for almost a century, there are still many questions. The pathophysiology
      is not sufficiently understood to allow finding more effective therapies. It is necessary to
      identify genetic determinants and thus potentially new pharmacological targets more adapted.

      The establishment of a biological database will test hypotheses concerning the genetic origin
      and thromboembolic process of atrial fibrillation and associated stroke.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Anticipated">April 23, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 23, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of DNA sample</measure>
    <time_frame>1 day (the day of the storage)</time_frame>
    <description>Quality is based on the measure of the purity of DNA with absorbance assay at 260/280nm on a spectrophotometer. For Plasma sample, purity is based on absence of hemolyzed blood by visual observation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Plasma sample</measure>
    <time_frame>1 day (the day of the storage)</time_frame>
    <description>Quality is based on the purity of Plasma sample that is based on absence of hemolyzed blood by visual observation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of preservation of the sample</measure>
    <time_frame>7 years (during all the duration of the collection)</time_frame>
    <description>The quality of preservation of the sample throughout the conservation duration is based on the number of freezing/thawing of each cryotube that will be notified. As weel as any interruption in the freezing process (power failure, freezer failure).</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group 1a</arm_group_label>
    <description>Patient with atrial fibrillation and without stroke history.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b</arm_group_label>
    <description>Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1c</arm_group_label>
    <description>Patient with atrial fibrillation and with stroke history.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Patients aged over 80 years old and without history of atrial fibrillation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Patient with cryptogenic stroke history before the age of 50.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood taken</intervention_name>
    <description>Collection of clinical data</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 1c</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood taken</intervention_name>
    <description>Collection of DNA</description>
    <arm_group_label>Group 1a</arm_group_label>
    <arm_group_label>Group 1b</arm_group_label>
    <arm_group_label>Group 1c</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood taken</intervention_name>
    <description>Collection of plasma</description>
    <arm_group_label>Group 1b</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Atrial fibrillation patient Stroke patient Patient over 80
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Group 1a:

          -  Inclusion Criteria :

               -  Atrial Fibrillation history

          -  Exclusion Criteria :

               -  No Atrial Fibrillation history

               -  patient who didn't signed consent

        Group 1b

          -  Inclusion Criteria :

               -  Atrial Fibrillation history

               -  Scheduled electrophysiological exploration or Atrial Fibrillation ablation

          -  Exclusion Criteria :

               -  No Atrial Fibrillation history

               -  pregnant women

               -  patient who didn't signed consent

        Group 1c

          -  Inclusion Criteria :

               -  Atrial Fibrillation history

               -  Stroke history

          -  Exclusion Criteria :

               -  patient who didn't signed consent

        Group 2

          -  Inclusion Criteria :

               -  patient over 80

               -  Electrocardiography : sinusal rhythm

               -  Transthoracic echocardiogram : no left atrial dilatation

          -  Exclusion Criteria :

               -  atrial fibrillation history

               -  Transthoracic echocardiogram : Left atria &gt;25cm², &gt; 34m/m2), LVEF (left
                  ventricular ejection fraction) &lt; 50%

               -  Electrocardiography : QRS &gt; 90 ms

               -  cardiac pathologies (excepted hypertension and valvulopathies)

               -  History of stroke and transient ischemic attack

               -  patient who didn't signed consent

        Group 3

          -  Inclusion Criteria :

               -  cryptogenic stroke history before 50 yo

               -  No Atrial Fibrillation history

          -  Exclusion Criteria :

               -  Atrial Fibrillation history

               -  stroke over 50 yo

               -  patient who didn't signed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe CHEVALIER, PU-PH</last_name>
    <phone>04 72 35 70 27</phone>
    <phone_ext>+33</phone_ext>
    <email>philippe.chevalier@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie MOREL</last_name>
    <phone>04 72 35 73 81</phone>
    <phone_ext>+33</phone_ext>
    <email>elodie.morel01@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service neurologie Centre hospitalier Fleyriat</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <zip>01000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric PHILIPPEAU, PH</last_name>
      <phone>04.74.45.43.64</phone>
      <phone_ext>+33</phone_ext>
      <email>fphilippeau@ch-bourg01.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric PHILIPPEAU, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'urgences Neurovasculaires - service de neurologie vasculaire , Hôpital Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura MECHTOUFF, PH</last_name>
      <phone>04 72 35 67 47</phone>
      <phone_ext>+33</phone_ext>
      <email>laura.mechtouff@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Laura MECHTOUFF, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de rythmologie, hôpital cardiologique Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CHEVALIER, PU-PH</last_name>
      <phone>04 72 35 70 27</phone>
      <phone_ext>+33</phone_ext>
      <email>philippe.chevalier@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elodie MOREL</last_name>
      <phone>04 72 35 73 81</phone>
      <phone_ext>+33</phone_ext>
      <email>elodie.morel01@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe CHEVALIER, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de médecine gériatrique Centre hospitalier Lyon Sud, Groupement hospitalier Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc BONNEFOY, PU-PH</last_name>
      <phone>04 72 36 15 81</phone>
      <phone_ext>+33</phone_ext>
      <email>marc.bonnefoy@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Marc BONNEFOY, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

